Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
132P - Deciphering aggressive behavior in uterine inflammatory myofibroblastic tumors: Clinicopathological and molecular analysis
Presenter: Nikola Hajkova
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Exploring genomic instability at the single-cell level using a new method for the inference of copy number alterations
Presenter: Lucrezia Patruno
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - SPICE: Probabilistic reconstruction of copy-number evolution in cancer
Presenter: Abigail Bunkum
Session: Cocktail & Poster Display session
Resources:
Abstract
135P - Revealing the third kind of pathway of colorectal cancer developing from laterally spreading tumors
Presenter: Jianshe Yang
Session: Cocktail & Poster Display session
Resources:
Abstract
136P - Investigating the evolutionary and regulatory dynamics of acquired resistance to BTK inhibitors in activated B-cell diffuse large B-cell lymphoma cells
Presenter: Luminita Ruje
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Analysis of master regulatory transcription factors and their associated transcriptomic profiles in SCLC patients
Presenter: Janik Riese
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Rewiring of cis-regulatory and kinase signalling networks in acalabrutinib-resistant ABC DLBCL cells
Presenter: Pavel Artemov
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - MYC subgroups delineate specific transcriptomic landscape and shape response to radiotherapy in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - An unconditionally dynamic culture system for cancer stem cell
Presenter: Ya-Juan Zhu
Session: Cocktail & Poster Display session
Resources:
Abstract